Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human papillomavirus 58 major capsid protein L1 (HPV-58 L1) is the primary structural protein forming the outer shell of HPV-58 virions. It self-assembles into pentamers and, together with 71 other pentamers, builds an icosahedral capsid that protects the viral genome and mediates initial attachment to host cells[1][2][3][5]. L1 is highly immunogenic and serves as the key antigen in current prophylactic HPV vaccines, which exploit its ability to form virus-like particles (VLPs) that closely mimic the native virus structure and elicit strong neutralizing antibody responses[2][4][6]. Neutralizing antibodies raised against HPV-58 L1 specifically block HPV-58 infection by targeting surface-exposed loops on the L1 protein, preventing viral attachment and entry. Variation in L1 sequences can influence antibody binding and vaccine efficacy among different HPV genotypes[3][4][6].
Induction of neutralizing antibody response: vaccines containing recombinant HPV-58 L1 VLPs induce neutralizing antibodies that block virus attachment and entry into host cells
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human papillomavirus 58 major capsid protein L1 (HPV-58 L1).